LINKER-MM3
A Trial to Learn How Well Linvoseltamab works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants with Relapsed/Refractory Multiple Myeloma
What will happen during the trial?
This clinical trial is seeking approximately 380 participants. This is a Phase 3 trial that is randomized and open-label. Randomized means that the treatment each participant receives will be randomly assigned by a computer program. Open-label means that both the participants and the trial doctors will know what treatment the participants are receiving. Participants will be screened up to 28 days before the trial and then participate in the trial for as long as they are receiving benefit or until they leave the trial for another reason.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 3
- Enrollment
- 380 patients (estimated)
- Sponsors
- Regeneron Pharmaceuticals
- Tags
- Bispecific Antibody, B-Cell Maturation Antigen (BCMA), CD3, Randomization
- Trial Type
- Treatment
- Last Update
- 1 week ago
- SparkCures ID
- 1834
- NCT Identifier
- NCT05730036
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.